Rabacfosadine - CISMeF

Preferred Label : Rabacfosadine;

NCIt definition : An acyclic nucleotide phosphonate prodrug and polymerase inhibitor that can potentially be used for its antineoplastic activity in the treatment of lymphoma in dogs. Upon administration, rabacfosadine is hydrolyzed intracellularly to 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2, 6-diaminopurine (cPrPMEDAP) and subsequently deaminated to 9-(2-phosphonylmethoxyethyl) guanine (PMEG) and phosphorylated to PMEG diphosphate (PMEGpp). PMEGpp binds to and inhibits DNA polymerases. This inhibits DNA synthesis, resulting in S phase arrest and induction of apoptosis.;

UNII : M39BO43J9W;

InChIKey : ANSPEDQTHURSFQ-KBPBESRZSA-N;

CAS number : 859209-74-8;

NCI Metathesaurus CUI : CL553466;

Details

Origin ID

C152134;

UMLS CUI

C4519203;

Automatic exact mappings (from CISMeF team)
- rabacfosadine [MeSH concept]
- rabacfosadine [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- rabacfosadine [MeSH Supplementary Concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients